Cited by 123Autophagy in Disease and TherapyFlavonoids in Medical ResearchInfluenza Virus Research Studies

Drug Screening for Autophagy Inhibitors Based on the Dissociation of Beclin1-Bcl2 Complex Using BiFC Technique and Mechanism of Eugenol on Anti-Influenza A Virus Activity

Open access
Dai, Jian-Ping, Zhao, Xiang-Feng, Zeng, Jun, Wan, Qian-Ying, Yang, Jia-Cai, Li, Wei-Zhong, Chen, Xiao-Xuan, Wang, Ge-Fei +1 more·2013·PLoS ONE

Abstract

Autophagy is involved in many human diseases, such as cancer, cardiovascular disease and virus infection, including human immunodeficiency virus (HIV), hepatitis C virus (HCV), influenza A virus (IAV) and coxsackievirus B3/B4 (CVB3/B4), so a drug screening model targeting autophagy may be very useful for the therapy of these diseases. In our study, we established a drug screening model based on the inhibition of the dissociation of Beclin1-Bcl2 heterodimer, an important negative regulator of autophagy, using bimolecular fluorescence complementation (BiFC) technique for developing novel autophagy inhibitors and anti-IAV agents. From 86 examples of traditional Chinese medicines, we found Syzygium aromaticum L. had the best activity. We then determined the anti-autophagy and anti-IAV activity of eugenol, the major active compound of Syzygium aromaticum L., and explored its mechanism of action. Eugenol could inhibit autophagy and IAV replication, inhibited the activation of ERK, p38MAPK and IKK/NF-κB signal pathways and antagonized the effects of the activators of these pathways. Eugenol also ameliorated the oxidative stress and inhibited the expressions of autophagic genes. We speculated that the mechanism underlying might be that eugenol inhibited the oxidative stress and the activation of ERK1/2, p38MAPK and IKK/NF-κB pathways, subsequently inhibited the dissociation of Beclin1-Bcl2 heterodimer and autophagy, and finally impaired IAV replication. These results might conversely display the reasonableness of the design of our screening model. In conclusion, we have established a drug screening model for developing novel autophagy inhibitor, and find eugenol as a promising inhibitor for autophagy and IAV infection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0061026

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CEO has shown antiviral activity against Ebola, influenza A virus, and herpes simplex virus types 1 and 2.

    “CEO has shown antiviral activity against Ebola [111], influenza A virus [112], and herpes simplex virus types 1 and 2 [111].”

    From Clove essential oil (Syzygium aromaticum L. Myrtaceae): Extraction, chemical composition, food applications, and essential bioactivity for human health (2021) · cites this paper as [112]

    Citation [112] is attached only to the influenza A claim. The Results (page unavailable) report that eugenol inhibited influenza A virus replication, but the Materials and Methods identify the tested eugenol as a purchased compound; the paper does not establish antiviral activity for CEO itself. The Ebola and herpes simplex claims are attributed to [111], not this source. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Dai, J.-P., Zhao, X.-F., Zeng, J., Wan, Q.-Y., Yang, J.-C., Li, W.-Z., Chen, X.-X., Wang, G.-F., & Li, K.-S.
Affiliations
Shantou University (CN)
Venue
PLoS ONE
Published
2013-04-16
Volume
8
Issue
4
Pages
e61026
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2169454801
Cited by
123
References
45
Citations by year
2026: 4 · 2025: 6 · 2024: 11 · 2023: 11 · 2022: 17 · 2021: 17 · 2020: 5 · 2019: 7 · 2018: 9 · 2017: 9 · 2016: 5 · 2015: 12 · 2014: 6 · 2013: 4
FWCI
6.56
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
National Natural Science Foundation of China (81172795, 81001322, 30972766, 31170852)
Topics
  • Health Sciences › Medicine › Epidemiology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Pharmacology › Flavonoids in Medical Research
  • Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
Keywords
autophagy inhibitors, influenza A virus, eugenol, Syzygium aromaticum, traditional Chinese medicine, drug screening model, oxidative stress, ERK signaling, p38 MAPK signaling, IKK/NF-κB signaling, antiviral activity
MeSH terms
Antiviral Agents, Autophagy, Cell Line, Drug Evaluation, Preclinical, Drugs, Chinese Herbal, Eugenol, Humans, Influenza A virus, Syzygium

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review